Characteristic gene expression In stromal cells of gastric cancers among atomic-bomb survivors

International Journal of Cancer

Volumn 124, Issue 5, 2009, Pages 1112-1121

  Oue, Naohide ^a   Sentani, Kazuhiro ^a   Sakamoto, Naoya ^a   Motoshita, Junichi ^a   Nishisaka, Takashi ^b   Fukuhara, Toshiyuki ^b   Matsuura, Hiroo ^c   Sasaki, Hiroki ^d   Nakachi, Kei ^e   Yasui, Wataru ^a,f  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA PREFECTURAL HOSPITAL   (Japan)

^c HIROSHIMA CITY HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^e RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

^f HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Atomic bomb; Gastric cancer; Osteonectin; Radiation carcinogenesis; Versican

Indexed keywords

OSTEONECTIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RIBONUCLEASE A; RNA; TRANSKETOLASE; VERSICAN; UNCLASSIFIED DRUG; VCAN PROTEIN, HUMAN;

ARTICLE; ATOMIC BOMB SURVIVOR; CANCER GROWTH; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; STOMACH CANCER; STROMA CELL; THBS2 GENE; AGED; ATOMIC BOMB; CHEMISTRY; DNA MICROARRAY; FEMALE; GENETICS; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; RADIATION INJURY; STOMACH TUMOR; SURVIVOR;

AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASMS, RADIATION-INDUCED; NUCLEAR WEAPONS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEONECTIN; STOMACH NEOPLASMS; STROMAL CELLS; SURVIVORS; VERSICANS;

EID: 58749085054     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24060     Document Type: Article

References (40)

1. Thompson DE, Mabuchi K, Ron E, Soda M, Tokunaga M, Ochikubo S, Sugimoto S, Ikeda T, Terasaki M, Izumi S, Preston DL. Cancer incidence in atomic bomb survivors, part II: solid tumors, 1958-1987. Radiat Res 1994;137:S17-67.
2. Takeshima Y, Seyama T, Bennett WP, Akiyama M, Tokuoka S, Inai K, Mabuchi K, Land CE, Harris CC. p53 mutations in lung cancers from non-smoking atomic-bomb survivors. Lancet 1993;342:1520-1.
3. Takahashi K, Eguchi H, Arihiro K, Ito R, Koyama K, Soda M, Cologne J, Hayashi Y, Nakata Y, Nakachi K, Hamatani K. The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose. Mol Carcinog 2007;46:242-8.
4. Yasui W, Que N, Kitadai Y, Nakayama H. Recent advances in molecular pathobiology of gastric carcinoma. In: Kaminishi M, Takubo K, Mafune K, eds. The diversity of gastric carcinoma pathogenesis: diagnosis, and therapy. Tokyo: Springer, 2005.51-71.
5. Ushijima T, Sasako M. Focus on gastric cancer. Cancer Cell 2004;5:121-5.
6. Preston DL, Shimizu Y, Pierce DA, Suyaraa A, Mabuchi K. Studies of mortality of atomic bomb survivors. Report 13: solid cancer and noncancer disease mortality: 1950-1997. Radiat Res 2003; 160:381- 407
7. Iwamoto KS, Mizuno T, Tokuoka S, Mabuchi K, Seyama T. Frequency of p53 mutations in hepatocellular carcinomas from atomic bomb survivors. J Natl Cancer Inst 1998;90:1167-8.
8. Schwartz NB, Pirok EW, 3rd, Mensch JR, Jr., Domowicz MS. Domain organization, genomic structure, evolution, and regulation of expression of the aggrecan gene family. Prog Nucleic Acid Res Mol Biol 1999;62:177-225.
9. Rahmani M, Wong BW, Ang L, Cheung CC, Carthy JM, Walinski H, McManus BM. Versican: signaling to transcriptional control pathways. Can J Physiol Pharmacol 2006;84:77-92.
10. Yang BL, Zhang Y, Cao L, Yang BB. Cell adhesion and proliferation mediated through the Gl domain of versican. J Cell Biochera 1999; 72:210-20.
11. Ricciardelli C, Russell DL, Ween MP, Mayne K, Suwiwat S, Byers S, Marshall VR, Tilley WD, Horsfall DJ. Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J Biol Chem 2007;282:10814-25.
12. Ricciardelli C, Brooks JH, Suwiwat S, Sakko AJ, Mayne K, Raymond WA, Seshadri R, LeBaron RG, Horsfall DJ. Regulation of stromal versican expression by breast cancer cells and importance to relapsefree survival in patients with node-negative primary breast cancer. Clin Cancer Res 2002;8:1054-60.
13. Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR, Horsfall DJ. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin Cancer Res 1998;4:963-71.
14. Yan Q, Sage EH. SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem 1999;47:1495-506.
15. Koukourakis MI, Giatromanolaki A, Brekken RA, Sivridis E, Gatter KC, Harris AL, Sage EH. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hvpoxia/acidity and with poor prognosis of patients. Cancer Res 2003:63:5376-80.
16. Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA, Yeo C, Iacobuzio-Donahue C, Goggins M. Peri tumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007;25:319-25.
17. Jacob K, Webber M, Benayahu D, Kleimnan HK. Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res 1999;59:4453-7.
18. Briggs J, Chamboredon S, Castellazzi M, Kerry JA, Bos TJ. Transcriptional upregulation of SPARC, in response to c-Jun overexpression. contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene 2002;21:7077-91.
19. Theocharis AD, Vynios DH, Papageorgakopoulou N, Skandalis SS, Theocharis DA. Altered content composition and structure of glycosaminoglycans and proteoglycans in gastric carcinoma. Int J Biochem Cell Biol 2003;35:376-90.
20. Maeng HY, Song SB, Choi DK, Kim KE, Jeong HY, Sakaki Y, Furihata C. Osteonectin-expressing cells in human stomach cancer and their possible clinical significance. Cancer Lett 2002; 184:117-21.
21. Sobin LH, Wittekind CH, eds. TNM classification of malignant tumors, 6th edit. New York: Wiley-Liss, 2002.65-8.
22. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histoclinical classification. Acta Pathol Microbiol Scand 1965;64:31-49.
23. Yasui W, One N. Systematic collection of tissue specimens and molecular pathological analysis of newly diagnosed solid cancers among atomic bomb survivors. Int Congr Ser 2007;1299:81-6.
24. Preston DL, Pierce DA, Shiraizu Y, Cullings HM, Fujita S, Funamoto S, Kodama K. Effect of recent changes in atomic bomb survivor dosimetry on cancer mortality risk estimates. Radiat Res 2004; 162:377-89.
25. Nagao K, Togawa N, Fujii K, Uchikawa H, Kohno Y, Yamada M, Miyashita T. Detecting tissue-specific alternative splicing and disease-associated aberrant splicing of the PTCH gene with exon junction microarrays. Hum Mol Genet 2005; 14:3379-88.
26. Oue N, Haraai Y, Mitani Y, Matsumura S, Oshimo Y, Aung PP, Kuraoka K, Nakayama H, Yasui W. Gene expression profile of gastric carcinoma: identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression. Cancer Res 2004;64:2397-405.
27. Hasegawa S, Furukawa Y, Li M, Satoh S, Kato T, Watanabe T, Katagiri T, Tsunoda T, Yamaoka Y, Nakamura Y. Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. Cancer Res 2002;62:7012-17.
28. Inoue H, Matsuyama A, Mimori K, Ueo H, Mori M, Prognostic score of gastric cancer determined by cDNA microarray. Clin Cancer Res 2002:8:3475-9.
29. Zembutsu H, Ohnishi Y, Tsunoda T, Furukawa Y, Katagiri T, Ueyama Y, Tamaoki N, Nomura T, Kitahara O, Yanagawa R, Hirata K, Nakamura Y. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res 2002;62:518-27.
30. Mizoshita T, Tsukamoto T, Nakanishi H, Inada K, Ogasawara N, Joh T, Itoh M, Yamamura Y, Tatematsu M. Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis. J Cancer Res Clin Oncol 2003;129:727-34.
31. Bode-Lesniewska B, Dours-Zimmermann MT, Odermatt BF, Briner J, Heitz PU, Zimmermann DR. Distribution of the large aggregating proteoglycan versican in adult human tissues. J Histochem Cytochem 1996;44:303-12.
32. Tatematsu M, Tsukamoto T, Inada K. Stem cells and gastric cancer: role of gastric and intestinal mixed intestinal metaplasia. Cancer Sci 2003;94:135-41.
33. Kushiraa R, Muller W, Stolte M, Borchard F. Differential p53 protein expression in stomach adenomas of gastric and intestinal phenotypes: possible sequences of p53 alteration in stomach carcinogenesis. Virchows Arch 1996;428:223-7.
34. Endoh Y, Tamura G, Ajioka Y, Watanabe H, Motoyama T. Frequent hypermethylation of the hMLHl gene promoter in differentiated-type tumors of the stomach with the gastric foveolar phenotype. Am J Pathol 2000;157:717-22.
35. Motoshita J, Oue N, Nakayama H, Kuraoka K, Aung PP, Taniyama K, Matsusaki K, Yasui w. DNA methylation profiles of differentiated-tvpe gastric carcinomas with distinct mucin phenotypes. Cancer Sci 2005;96:474-9.
36. Sakko AI, Ricciardelli C, Mayne K. Tilley WD, Lebaron RG, Horsfall DJ. Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor betal. Cancer Res 2001 ;61:926-30.
37. Re3ed MJ, Vernon RB, Abrass IB, Sage EH. TGF-beta 1 induces the expression of type T collagen and SPARC, and enhances contraction of collagen gels, by fibroblasts from young and aged donors. J Cell Physiol 1994;158:169-79.
38. Bhowraick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004;303:848-51.
39. Suehiro S, Nagasue N, Abe S, Ogawa Y, Sasaki Y. Carcinoma of the stomach in atomic bomb survivors. A comparison of ciinicopathologic features to the general population. Cancer 1986;57:1894-8.
40. Le Bail B, Faouzi S, Boussarie L, Guirouilh I, Blanc IF, Carles J, Bioulac-Sage P, Balabaud C, Rosenbaum J. Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma, J Pathol 1999:189: 46-52.